Solti Breast Cancer Research Group
Clinical trials sponsored by Solti Breast Cancer Research Group, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a 4-Week drug combo shrink breast tumors before surgery? Results expected Dec 2026 (estimated)
-
Could a pill replace chemo for some breast cancer patients?
Disease control OngoingThis phase 2 trial is testing whether a combination of ribociclib (Kisqali) and letrozole can safely replace chemotherapy for people with high-risk ER+/HER2- breast cancer. About 1100 participants will first receive the drug combo before surgery. If their tumor shows a low risk o…
Phase 2 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug cocktail targets hard-to-treat breast cancer
Disease control OngoingThis phase 2 trial is testing a combination of three drugs—atezolizumab, trastuzumab, and vinorelbine—in people with HER2-positive advanced or metastatic breast cancer that has already been treated with trastuzumab and other anti-HER2 therapies. The study focuses on patients whos…
Phase 2 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Disease control
Last updated Jun 26, 2026 15:16 UTC
-
Scientists hunt for clues to predict T-DXd success in metastatic cancer
Knowledge-focused OngoingThis study collects tumor and blood samples from 180 people with metastatic cancer who are receiving or have received the drug T-DXd. Researchers will analyze these samples to find genetic markers that predict whether the drug will work well. The goal is to improve treatment deci…
Sponsor: SOLTI Breast Cancer Research Group • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:00 UTC